<VariationArchive RecordType="classified" VariationID="1807818" VariationName="GRCh37/hg19 2p16.3(chr2:50838595-51078612)x1" VariationType="copy number loss" Accession="VCV001807818" Version="1" NumberOfSubmissions="1" NumberOfSubmitters="1" DateLastUpdated="2022-12-31" DateCreated="2022-12-31" MostRecentSubmission="2022-12-31">
  <RecordStatus>current</RecordStatus>
  <Species>Homo sapiens</Species>
  <ClassifiedRecord>
    <SimpleAllele AlleleID="1864822" VariationID="1807818">
      <GeneList>
        <Gene Symbol="NRXN1" FullName="neurexin 1" GeneID="9378" HGNC_ID="HGNC:8008" Source="calculated" RelationshipType="within single gene">
          <Location>
            <CytogeneticLocation>2p16.3</CytogeneticLocation>
            <SequenceLocation Assembly="GRCh38" AssemblyAccessionVersion="GCF_000001405.38" AssemblyStatus="current" Chr="2" Accession="NC_000002.12" start="49918503" stop="51032132" display_start="49918503" display_stop="51032132" Strand="-" />
            <SequenceLocation Assembly="GRCh37" AssemblyAccessionVersion="GCF_000001405.25" AssemblyStatus="previous" Chr="2" Accession="NC_000002.11" start="50145642" stop="51259673" display_start="50145642" display_stop="51259673" Strand="-" />
          </Location>
          <OMIM>600565</OMIM>
          <Haploinsufficiency last_evaluated="2021-06-08" ClinGen="https://www.ncbi.nlm.nih.gov/projects/dbvar/ISCA/isca_gene.cgi?sym=NRXN1">Sufficient evidence for dosage pathogenicity</Haploinsufficiency>
          <Triplosensitivity last_evaluated="2021-06-08" ClinGen="https://www.ncbi.nlm.nih.gov/projects/dbvar/ISCA/isca_gene.cgi?sym=NRXN1">No evidence available</Triplosensitivity>
        </Gene>
      </GeneList>
      <Name>GRCh37/hg19 2p16.3(chr2:50838595-51078612)x1</Name>
      <VariantType>copy number loss</VariantType>
      <Location>
        <CytogeneticLocation>2p16.3</CytogeneticLocation>
        <SequenceLocation Assembly="GRCh37" AssemblyAccessionVersion="GCF_000001405.25" forDisplay="true" AssemblyStatus="previous" Chr="2" Accession="NC_000002.11" innerStart="50838595" innerStop="51078612" display_start="50838595" display_stop="51078612" />
      </Location>
    </SimpleAllele>
    <RCVList>
      <RCVAccession Title="GRCh37/hg19 2p16.3(chr2:50838595-51078612)x1 AND not provided" Accession="RCV002472624" Version="1">
        <ClassifiedConditionList TraitSetID="9460">
          <ClassifiedCondition DB="MedGen" ID="CN517202">not provided</ClassifiedCondition>
        </ClassifiedConditionList>
        <RCVClassifications>
          <GermlineClassification>
            <ReviewStatus>criteria provided, single submitter</ReviewStatus>
            <Description DateLastEvaluated="2021-12-02" SubmissionCount="1">Pathogenic</Description>
          </GermlineClassification>
        </RCVClassifications>
      </RCVAccession>
    </RCVList>
    <Classifications>
      <GermlineClassification DateLastEvaluated="2021-12-02" NumberOfSubmissions="1" NumberOfSubmitters="1" DateCreated="2022-12-31" MostRecentSubmission="2022-12-31">
        <ReviewStatus>criteria provided, single submitter</ReviewStatus>
        <Description>Pathogenic</Description>
        <ConditionList>
          <TraitSet ID="9460" Type="Disease" ContributesToAggregateClassification="true">
            <Trait ID="17556" Type="Disease">
              <Name>
                <ElementValue Type="Preferred">not provided</ElementValue>
                <XRef ID="13DG0619" DB="Developmental Genetics Unit, King Faisal Specialist Hospital &amp; Research Centre" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">none provided</ElementValue>
              </Name>
              <AttributeSet>
                <Attribute Type="public definition">The term 'not provided' is registered in MedGen to support identification of submissions to ClinVar for which no condition was named when assessing the variant. 'not provided' differs from 'not specified', which is used when a variant is asserted to be benign, likely benign, or of uncertain significance for conditions that have not been specified.</Attribute>
              </AttributeSet>
              <XRef ID="CN517202" DB="MedGen" />
            </Trait>
          </TraitSet>
        </ConditionList>
      </GermlineClassification>
    </Classifications>
    <ClinicalAssertionList>
      <ClinicalAssertion ID="5420353" SubmissionDate="2022-12-28" DateLastUpdated="2022-12-31" DateCreated="2022-12-31">
        <ClinVarSubmissionID localKey="C9405|not provided|copy:1" submittedAssembly="GRCh37" />
        <ClinVarAccession Accession="SCV002772492" DateUpdated="2022-12-31" DateCreated="2022-12-31" Type="SCV" Version="1" SubmitterName="Quest Diagnostics Nichols Institute San Juan Capistrano" OrgID="500110" OrganizationCategory="laboratory" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2021-12-02">
          <ReviewStatus>criteria provided, single submitter</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
          <Comment>The loss of 2p16.3 involves multiple exons of the 5' region of gene NRXN1 (OMIM 600565). This genomic loss may predispose to a wide spectrum of developmental disorders (Al Shehhi et al., Eur J Med Genet. 2018 Jul 18. Pii: S1769-7212(18)30079-X., PMID: 30031152; Ching et al., Am J Med Genet B Neuropsychiatr Genet. 2010 Jun 5;153B(4):937-47, PMID: 20468056). Most individuals with NRXN1 exonic deletions have developmental delay (particularly speech), abnormal behaviors, and mild dysmorphic features. In a cohort of over 20 individuals with NRXN1 exonic deletions, autism spectrum disorders were diagnosed in 43% (10/23), and 16% (4/25) had epilepsy (Dabell MP, et al., Am J Med Genet A. 2013 Apr;161A(4):717-31; PMID: 23495017). Data from a recent study evaluating NRXN1 deletions suggests partial deletions near the 5' end have a higher penetrance related to the expression of neurodevelopmental phenotypes compared to those at the 3' end (Lowther et al. Genet Med. 2017 Jan;19(1):53-61. PMID: 27195815). A</Comment>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <AttributeSet>
          <Attribute Type="AssertionMethod">ACMG/ClinGen CNV Guidelines, 2019</Attribute>
          <Citation>
            <ID Source="PubMed">31690835</ID>
          </Citation>
        </AttributeSet>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>unknown</Origin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>unknown</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>clinical testing</MethodType>
              <MethodAttribute>
                <Attribute Type="StructVarMethodType">Oligo array</Attribute>
              </MethodAttribute>
            </Method>
            <ObservedData>
              <Attribute Type="Description">not provided</Attribute>
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <VariantType>copy number loss</VariantType>
          <Location>
            <SequenceLocation Assembly="GRCh37" Chr="2" innerStart="50838595" innerStop="51078612" />
          </Location>
          <AttributeSet>
            <Attribute Type="AbsoluteCopyNumber">1</Attribute>
          </AttributeSet>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <Name>
              <ElementValue Type="Preferred">not provided</ElementValue>
            </Name>
          </Trait>
        </TraitSet>
        <SubmissionNameList>
          <SubmissionName>SUB12478099</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
    </ClinicalAssertionList>
    <TraitMappingList>
      <TraitMapping ClinicalAssertionID="5420353" TraitType="Disease" MappingType="Name" MappingValue="not provided" MappingRef="Preferred">
        <MedGen CUI="CN517202" Name="not provided" />
      </TraitMapping>
    </TraitMappingList>
  </ClassifiedRecord>
</VariationArchive>

